IP Library Granted Patent US 11,185,518
Granted Patent B2
US 11,185,518 · App. 16/783,886 · Granted Nov 30, 2021

S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer

Inventor: Gary Millet (Salt Lake City, UT)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/19A23L29/035A23L33/10A23L33/12A23L33/30A61K9/14A61K9/20A61K9/48A61K47/14A61P3/08A23L33/155A23V2002/00A23V2250/182A23V2250/192A23V2250/1946A23V2250/7106
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,185,518
App. No.
16/783,886
Granted
Nov 30, 2021
Kind
B2
Abstract

Ketogenic compositions include a mixture of optically pure S-beta-hydroxybutyrate salts and acid(s) or non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contains from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Claims (59)

1. A composition for administering ketone bodies and/or ketone body precursors to a subject, the composition comprising:

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate enriched with S-beta-hydroxybutyrate so as to contain more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate, with the proviso that:

when the composition comprises the optically pure S-beta-hydroxybutyrate it includes a mixture of at least one optically pure S-beta-hydroxybutyrate salt and optically pure S-beta-hydroxybutyric acid; or

when the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate it includes a mixture of:

at least two S-beta-hydroxybutyrate salts;

at least two R-beta-hydroxybutyrate salts; and

at least one of S- or R-beta-hydroxybutyric acid.

2. The composition of claim 1 , wherein the composition comprises the optically pure S-beta-hydroxybutyrate and includes a plurality of optically pure S-beta-hydroxybutyrate salts and the optically pure S-beta-hydroxybutyric acid and is free of R-beta-hydroxybutyrate salts and R-beta-hydroxybutyric acid.

3. The composition of claim 1 , wherein the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate and contains from 50.5% to 99.5% by enantiomeric equivalents of S-beta-hydroxybutyrate and 49.5% to 0.5% by enantiomeric equivalents of R-beta-hydroxybutyrate.

4. The composition of claim 3 , wherein the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate contains from 51% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate and 49% to 1% by enantiomeric equivalents of R-beta-hydroxybutyrate.

5. The composition of claim 3 , wherein the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate contains from 52% to 98% by enantiomeric equivalents of S-beta-hydroxybutyrate and 48% to 2% by enantiomeric equivalents of R-beta-hydroxybutyrate.

6. The composition of claim 1 , wherein the composition comprises 90% to 99.9% by molar equivalents of at least one optically pure S-beta-hydroxybutyrate salt or 90% to 99.9% by molar equivalents of combined S-beta-hydroxybutyrate and R-beta-hydroxybutyrate salts and 10% to 0.1% by molar equivalents of S-beta-hydroxybutyric acid and/or R-beta-hydroxybutyric acid.

7. The composition of claim 1 , wherein the composition comprises 75% to 99.9% by molar equivalents of at least one optically pure S-beta-hydroxybutyrate salt or 75% to 99.9% by molar equivalents of combined S-beta-hydroxybutyrate and R-beta-hydroxybutyrate salts and 25% to 0.1% by molar equivalents of S-beta-hydroxybutyric acid and/or R-beta-hydroxybutyric acid.

8. The composition of claim 1 , wherein the non-racemic mixture comprises 85% to 99.8% by molar equivalents of at least one optically pure S-beta-hydroxybutyrate salt or 55% to 99.8% by molar equivalents of combined S-beta-hydroxybutyrate and R-beta-hydroxybutyrate salts and 15% to 0.2% by molar equivalents of S-beta-hydroxybutyric acid and/or R-beta-hydroxybutyric acid.

9. The composition of claim 1 , wherein the composition comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of S-beta-hydroxybutyrate and/or R-beta-hydroxybutyrate.

10. The composition of claim 1 , further comprising at least one short chain fatty acid having less than 6 carbons, or a mono-, di- or triglyceride of the at least one short chain fatty acid.

11. The composition of claim 1 , further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.

12. A composition for administering ketone bodies and/or ketone body precursors to a subject, the composition comprising:

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate enriched with S-beta-hydroxybutyrate so as to contain more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate, with the proviso that:

when the composition comprises the optically pure S-beta-hydroxybutyrate it includes a mixture of at least one optically pure S-beta-hydroxybutyrate salt and optically pure S-beta-hydroxybutyric acid; or

when the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate it includes a mixture of:

at least one S-beta-hydroxybutyrate salt;

at least one R-beta-hydroxybutyrate salt; and

at least one of S- or R-beta-hydroxybutyric acid,

wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository.

13. The composition of claim 12 , wherein the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate and contains from 50.5% to 99.5% by enantiomeric equivalents of S-beta-hydroxybutyrate and 49.5% to 0.5% by enantiomeric equivalents of R-beta-hydroxybutyrate.

14. The composition of claim 12 , wherein the composition comprises 75% to 99.9% by molar equivalents of at least one optically pure S-beta-hydroxybutyrate salt or 75% to 99.9% by molar equivalents of combined S-beta-hydroxybutyrate and R-beta-hydroxybutyrate salts and 25% to 0.1% by molar equivalents of S-beta-hydroxybutyric acid and/or R-beta-hydroxybutyric acid.

15. The composition of claim 12 , wherein the composition comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of S-beta-hydroxybutyrate.

16. The composition of claim 12 , further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.

17. The composition of claim 12 , further comprising:

a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository.

18. A kit for administering ketone bodies to a subject, comprising:

a composition as in claim 1 ;

a container in which the composition is placed; and

a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 0.5 g to about 25 g of the optically pure S-beta-hydroxybutyrate or the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate.

19. The kit of claim 18 , wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, and keg.

20. The kit of claim 18 , wherein the measuring device is selected from the group consisting of cup, scoop, syringe, dropper, spatula, spoon, and colonic irrigation device.

21. A composition for administering ketone bodies and/or ketone body precursors to a subject, the ketone body composition comprising:

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate enriched with S-beta-hydroxybutyrate so as to contain more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate,

wherein the composition comprises one or more salts of S-beta-hydroxybutyrate selected from the group consisting of sodium salt, potassium salt, magnesium salt, transition metal salt, and amino acid salt.

22. A composition for administering ketone bodies and/or ketone body precursors to a subject, the composition comprising:

optically pure S-beta-hydroxybutyrate,

wherein the composition comprises S-beta-hydroxybutyric acid and at least one 5-beta-hydroxybutyrate salt,

wherein the composition is free of R-beta-hydroxybutyrate salts and R-beta-hydroxybutyric acid.

23. A composition for administering ketone bodies and/or ketone body precursors to a subject, the composition comprising:

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate enriched with S-beta-hydroxybutyrate so as to contain at least 93% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and up to 7% and greater than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate, with the proviso that:

when the composition comprises the optically pure S-beta-hydroxybutyrate it includes at least one optically pure S-beta-hydroxybutyrate salt and optically pure S-beta-hydroxybutyric acid; or

when the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate it includes a mixture of:

at least one S-beta-hydroxybutyrate salt;

at least one R-beta-hydroxybutyrate salt; and

at least one of S- or R-beta-hydroxybutyric acid.

24. A composition for administering ketone bodies and/or ketone body precursors to a subject, the composition comprising:

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate enriched with S-beta-hydroxybutyrate so as to contain more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate, with the proviso that:

when the composition comprises the optically pure S-beta-hydroxybutyrate it includes 75% to less than 100% by molar equivalents of at least one optically pure S-beta-hydroxybutyrate salt and greater than 0% and up to 25% by molar equivalents of optically pure S-beta-hydroxybutyric acid, or when the composition comprises the non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate it includes:

at least one S-beta-hydroxybutyrate salt;

at least one R-beta-hydroxybutyrate salt; and

at least one of S- or R-beta-hydroxybutyric acid,

wherein the non-racemic mixture includes 75% to less than 100% by molar equivalents of combined S-beta-hydroxybutyrate and R-beta-hydroxybutyrate salts, and

wherein the non-racemic mixture includes greater than 0% and up to 25% by molar equivalents of S- and/or R-beta-hydroxybutyric acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2020
From: MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 051744/0776 →
Continuity (5)
Continuation In Part 16272192 · Feb 11, 2019
Continuation In Part 16224485 · Dec 18, 2018
Division 15936849 · Mar 27, 2018
Provisional Application 62607578 · Dec 19, 2017
Related Publication 20200170982A1 · Jun 4, 2020
Cited By (14)
US 12,186,297 US 12,251,362 US 12,329,734 US 12,350,243 US 12,433,912 US 12,472,200 US 12,496,283 US 12,514,841 US 12,521,378 US 12,533,331 US 12,533,346 US 12,551,455 US 12,599,579 US 12,622,889